tranexamic acid has been researched along with Meningeal Neoplasms in 6 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Meningeal Neoplasms: Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Based upon Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), the authors collected fully published English literature on the administration of tranexamic acid for patients undergoing intracranial meningioma surgery using the keywords ["tranexamic acid" and "meningioma"] and its synonyms from Cochrane Central Database, the WHO International Clinical Trials Registry Platform (ICTRP), ClinicalTrials." | 9.41 | A systematic review and meta-analysis of the effects of tranexamic acid in surgical procedure for intracranial meningioma. ( Chadid, DP; July, J; Quintero-Consuegra, M; Wijaya, JH, 2023) |
| "Tranexamic acid (TXA) is an antifibrinolytic that is widely used to reduce surgical bleeding." | 7.83 | Intravenous tranexamic acid for intracerebral meningioma resections: A randomized, parallel-group, non-inferiority trial. ( Li, S; Liu, M; Peng, Y; Sessler, DI; Wu, Y; Yan, X; Yang, J; Zeng, M; Zhang, L; Zhou, D, 2024) |
| "Tranexamic acid (TXA) has been proven to prevent thrombolysis and reduce bleeding and blood transfusion requirements in various surgical settings." | 7.30 | The effect of tranexamic acid on intraoperative blood loss in patients undergoing brain meningioma resections: Study protocol for a randomized controlled trial. ( Jin, H; Li, M; Li, S; Liu, M; Liu, X; Ma, T; Peng, Y; Wang, J; Wu, Y; Yang, J; Yu, H; Zeng, M; Zhang, L; Zhang, X, 2023) |
| " However, postoperative seizure, as one of the major adverse effects of TXA infusion, has been a concern that restricts its utility in neurosurgery." | 7.11 | Safety of intravenous tranexamic acid in patients undergoing supratentorial meningiomas resection: protocol for a randomised, parallel-group, placebo control, non-inferiority trial. ( Dong, J; Li, R; Li, S; Liu, X; Ma, T; Peng, Y; Wang, J; Yan, X; Zeng, M; Zhang, X, 2022) |
| "Tranexamic Acid (TXA) has been used in medical and surgical practice to reduce haemorrhage." | 7.01 | Tranexamic acid use in meningioma surgery - A systematic review and meta-analysis. ( Bakhsh, A; Brodbelt, AR; Clynch, AL; Gillespie, CS; Islim, AI; Jenkinson, MD; Keshwara, SM; Kumar, S; Mills, SJ; Millward, CP; Mustafa, MA; Richardson, GE; Zakaria, R, 2023) |
| "Based upon Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), the authors collected fully published English literature on the administration of tranexamic acid for patients undergoing intracranial meningioma surgery using the keywords ["tranexamic acid" and "meningioma"] and its synonyms from Cochrane Central Database, the WHO International Clinical Trials Registry Platform (ICTRP), ClinicalTrials." | 5.41 | A systematic review and meta-analysis of the effects of tranexamic acid in surgical procedure for intracranial meningioma. ( Chadid, DP; July, J; Quintero-Consuegra, M; Wijaya, JH, 2023) |
| "Tranexamic acid (TXA) is an antifibrinolytic that is widely used to reduce surgical bleeding." | 3.83 | Intravenous tranexamic acid for intracerebral meningioma resections: A randomized, parallel-group, non-inferiority trial. ( Li, S; Liu, M; Peng, Y; Sessler, DI; Wu, Y; Yan, X; Yang, J; Zeng, M; Zhang, L; Zhou, D, 2024) |
| "Tranexamic acid (TXA) has been proven to prevent thrombolysis and reduce bleeding and blood transfusion requirements in various surgical settings." | 3.30 | The effect of tranexamic acid on intraoperative blood loss in patients undergoing brain meningioma resections: Study protocol for a randomized controlled trial. ( Jin, H; Li, M; Li, S; Liu, M; Liu, X; Ma, T; Peng, Y; Wang, J; Wu, Y; Yang, J; Yu, H; Zeng, M; Zhang, L; Zhang, X, 2023) |
| " However, postoperative seizure, as one of the major adverse effects of TXA infusion, has been a concern that restricts its utility in neurosurgery." | 3.11 | Safety of intravenous tranexamic acid in patients undergoing supratentorial meningiomas resection: protocol for a randomised, parallel-group, placebo control, non-inferiority trial. ( Dong, J; Li, R; Li, S; Liu, X; Ma, T; Peng, Y; Wang, J; Yan, X; Zeng, M; Zhang, X, 2022) |
| "Tranexamic Acid (TXA) has been used in medical and surgical practice to reduce haemorrhage." | 3.01 | Tranexamic acid use in meningioma surgery - A systematic review and meta-analysis. ( Bakhsh, A; Brodbelt, AR; Clynch, AL; Gillespie, CS; Islim, AI; Jenkinson, MD; Keshwara, SM; Kumar, S; Mills, SJ; Millward, CP; Mustafa, MA; Richardson, GE; Zakaria, R, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 5 (83.33) | 2.80 |
| Authors | Studies |
|---|---|
| Li, S | 3 |
| Yan, X | 2 |
| Li, R | 1 |
| Zhang, X | 2 |
| Ma, T | 2 |
| Zeng, M | 3 |
| Dong, J | 1 |
| Wang, J | 3 |
| Liu, X | 2 |
| Peng, Y | 3 |
| Wijaya, JH | 1 |
| July, J | 1 |
| Quintero-Consuegra, M | 1 |
| Chadid, DP | 1 |
| Clynch, AL | 1 |
| Gillespie, CS | 1 |
| Richardson, GE | 1 |
| Mustafa, MA | 1 |
| Islim, AI | 1 |
| Keshwara, SM | 1 |
| Bakhsh, A | 1 |
| Kumar, S | 1 |
| Zakaria, R | 1 |
| Millward, CP | 1 |
| Mills, SJ | 1 |
| Brodbelt, AR | 1 |
| Jenkinson, MD | 1 |
| Yu, H | 1 |
| Liu, M | 2 |
| Yang, J | 2 |
| Wu, Y | 2 |
| Li, M | 1 |
| Zhang, L | 2 |
| Jin, H | 1 |
| Zhou, D | 1 |
| Sessler, DI | 1 |
| Hooda, B | 1 |
| Chouhan, RS | 1 |
| Rath, GP | 1 |
| Bithal, PK | 1 |
| Suri, A | 1 |
| Lamsal, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Parallel-group, Placebo Control, Non-inferiority Trial to Investigate the Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection[NCT04595786] | 600 participants (Actual) | Interventional | 2020-10-30 | Active, not recruiting | |||
| The Effect of Magnesium Sulphate on Intraoperative Blood Loss in Meningioma Patient Undergoing Craniotomy With Tumor Removal[NCT03558516] | Phase 3 | 80 participants (Actual) | Interventional | 2018-08-01 | Completed | ||
| Efficacy of Tranexamic Acid (TXA) in Humerus ORIF[NCT05802238] | Phase 2 | 130 participants (Anticipated) | Interventional | 2023-04-12 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Amount of cis-atracurium usage during surgery (NCT03558516)
Timeframe: Intraoperative period from skin was incised to the skin was closure, an average 5 hours.
| Intervention | mg/kg/hr (Mean) |
|---|---|
| Group NSS | 0.08 |
| Group Mg | 0.08 |
Amount of fentanyl usage during surgery (NCT03558516)
Timeframe: Intraoperative period from skin was incised to the skin was closure, an average 5 hours.
| Intervention | mcg/kg/hr (Mean) |
|---|---|
| Group NSS | 0.65 |
| Group Mg | 0.6 |
We measure the amount of blood loss in the operative room in suction box, gauze and plastic bag. The unit measure is millimeter. (NCT03558516)
Timeframe: Intraoperative period from skin was incised to the skin was closure, an average 5 hours.
| Intervention | ml (Median) |
|---|---|
| Group NSS | 510 |
| Group Mg | 500 |
The amount of blood transfusion in patient who required PRC transfusion intraoperatively. (NCT03558516)
Timeframe: Intraoperative period from skin was incised to the skin was closure, an average 5 hours.
| Intervention | unit of packed red cell (Median) |
|---|---|
| Group NSS | 2 |
| Group Mg | 1 |
Number of patients who required Intraoperative PRC transfusion (NCT03558516)
Timeframe: Intraoperative period from skin was incised to the skin was closure, an average 5 hours.
| Intervention | Participants (Count of Participants) |
|---|---|
| Group NSS | 10 |
| Group Mg | 7 |
"MOCA or Montreal Cognitive Assessment is a screening instrument used to facilitate the assessment of cognitive impairment.~MOCA scores range between 0-30, do higher values represent a better outcome. A score of 26 or over is considered to be normal. We measure Montreal assessment score for assess cognitive function after operation at postoperative day 3-7." (NCT03558516)
Timeframe: Postoperative day 3-7
| Intervention | score on the MOCA scale (Median) |
|---|---|
| Group NSS | 23 |
| Group Mg | 25 |
Amount of sevoflurane agents usage during surgery. The unit of measurement of volatile agent is minimum alveolar concentration (MAC). 1 MAC-hour was defined as 2% of sevoflurane for 1 hour duration. (NCT03558516)
Timeframe: Intraoperative period from skin was incised to the skin was closure, an average 5 hours.
| Intervention | average minimum alveolar concentration (Mean) |
|---|---|
| Group NSS | 0.65 |
| Group Mg | 0.66 |
2 reviews available for tranexamic acid and Meningeal Neoplasms
| Article | Year |
|---|---|
A systematic review and meta-analysis of the effects of tranexamic acid in surgical procedure for intracranial meningioma.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Meningeal Neoplasms; Meningioma; Middl | 2023 |
Tranexamic acid use in meningioma surgery - A systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Humans; Meningeal Neoplasms; Meningioma; Tranexamic A | 2023 |
4 trials available for tranexamic acid and Meningeal Neoplasms
| Article | Year |
|---|---|
Safety of intravenous tranexamic acid in patients undergoing supratentorial meningiomas resection: protocol for a randomised, parallel-group, placebo control, non-inferiority trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Humans; Meningeal Neoplasms; Men | 2022 |
The effect of tranexamic acid on intraoperative blood loss in patients undergoing brain meningioma resections: Study protocol for a randomized controlled trial.
Topics: Blood Loss, Surgical; Brain; Humans; Meningeal Neoplasms; Meningioma; Randomized Controlled Trials a | 2023 |
Intravenous tranexamic acid for intracerebral meningioma resections: A randomized, parallel-group, non-inferiority trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; Humans; Meningeal Neoplasms; Men | 2024 |
Effect of tranexamic acid on intraoperative blood loss and transfusion requirements in patients undergoing excision of intracranial meningioma.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; Hemostasis, Surgica | 2017 |
Effect of tranexamic acid on intraoperative blood loss and transfusion requirements in patients undergoing excision of intracranial meningioma.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; Hemostasis, Surgica | 2017 |
Effect of tranexamic acid on intraoperative blood loss and transfusion requirements in patients undergoing excision of intracranial meningioma.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; Hemostasis, Surgica | 2017 |
Effect of tranexamic acid on intraoperative blood loss and transfusion requirements in patients undergoing excision of intracranial meningioma.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Female; Hemostasis, Surgica | 2017 |